Alnylam Pharmaceuticals’ Post

Sometimes, proteins your body makes can cause or contribute to disease. These proteins can be either be faulty, or healthy. RNAi therapeutics are a type of medicine, pioneered by Alnylam, that treats disease by targeting and disabling specific mRNA (messenger RNA) which tell your body how to make these unwanted proteins. #ScienceCurious to learn more about the science of #RNAi? Click here: https://bit.ly/3oR8r2l #RNAiTherapeutics #siRNA #GeneSilencing #science

With warmer months and family gatherings ahead, summer is the perfect time to discuss health with your loved ones. Hear from Renee and her father, Julio, who uncovered a health mystery that goes back generations at a family reunion. Learn more about #hATTR #amyloidosis here: https://bit.ly/3QPohJd #hATTRoadTrip

Proteins are the "workers" in the biochemistry of life and are critical to almost everything your body does, but sometimes, they can also cause or contribute to disease. RNAi therapeutics, which were pioneered by Alnylam, work by preventing the production of specific unwanted proteins. #ScienceCurious to learn more about the science of #RNAi? Read more here: https://bit.ly/3oR8r2l #RNAiTherapeutics #siRNA #GeneSilencing #science

What a week last week! Every Alnylam achievement, RNAi therapeutics advancement and milestone (such as our HELIOS-B topline data, which we were celebrating), is made possible because of the passion, innovation and perseverance of our 2,000 employees who are unwavering in their dedication to our mission. Together, we are leading the #RNAiRevolution. #RNAiTherapeutics #RNAi #siRNA #CompanyCulture

Healthcare Professionals: #hATTR #amyloidosis is a progressive and often fatal disease that affects multiple organs and tissues, resulting in a highly varied symptom presentation. Learn more about some different patient types that could be in your practice. https://bit.ly/3NuMgL9

RNA interference (RNAi) is a naturally occurring process of gene regulation that is already at work inside your body. RNAi therapeutics, which were pioneered by Alnylam, utilize this process to silence the genes that cause or contribute to disease. #ScienceCurious to learn more about #RNAi? Click here: https://bit.ly/3oR8r2l #RNAiTherapeutics #siRNA #GeneSilencing #RNA

An Alnylam team took steps to raise funds for the Huntington's Disease Society of America —literally. 👣 With kids in tow, colleagues participated in Team Hope Walk last weekend on Castle Island in Boston. We’re raising awareness about this devastating #RareDisease. Learn more about #HuntingtonsDisease: https://hdsa.org/

Dr. Fontana, an investigator on the HELIOS-B Phase 3 study of vutrisiran, an investigational #RNAi therapeutic in development for the treatment of #ATTR #amyloidosis with cardiomyopathy, shares her thoughts on the positive topline results. Full results will be presented at an upcoming medical meeting. #RNAiTherapeutics

Our CEO Dr. Yvonne Greenstreet shares her thoughts on the positive Phase 3 topline results from our HELIOS-B study of vutrisiran, an investigational #RNAi therapeutic in development for the treatment of #ATTR #amyloidosis w/ cardiomyopathy. Read the press release: https://bit.ly/3VwvRtY #RNAitherapeutics #siRNA